99 related articles for article (PubMed ID: 12577193)
1. Overcoming resistance: virologic response to a salvage regimen with the combination of ritonavir plus indinavir.
Casado JL; Moreno A; Martí-Belda P; Sabido R; Pinheiro S; Bermudez E; Antela A; Dronda F; Perez-Elías MJ; Moreno S
HIV Clin Trials; 2003; 4(1):21-8. PubMed ID: 12577193
[TBL] [Abstract][Full Text] [Related]
2. Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.
Casado JL; Dronda F; Hertogs K; Sabido R; Antela A; Martí-Belda P; Dehertogh P; Moreno S;
AIDS Res Hum Retroviruses; 2001 Jan; 17(2):93-8. PubMed ID: 11177388
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with indinavir, ritonavir, and delavirdine and nucleoside reverse transcriptase inhibitors in patients with HIV/AIDS who have failed multiple antiretroviral combinations.
Grodesky M; Acosta EP; Fujita N; Mason S; Gerber JG
HIV Clin Trials; 2001; 2(3):193-9. PubMed ID: 11590527
[TBL] [Abstract][Full Text] [Related]
4. A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response.
Casado JL; Moreno A; Sabido R; Martí-Belda P; Antela A; Dronda F; Perez-Elías MJ; Moreno S
HIV Clin Trials; 2000; 1(1):13-9. PubMed ID: 11590485
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
Ghosn J; Lamotte C; Ait-Mohand H; Wirden M; Agher R; Schneider L; Bricaire F; Duvivier C; Calvez V; Peytavin G; Katlama C
AIDS; 2003 Jan; 17(2):209-14. PubMed ID: 12545081
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures.
Campo RE; Moreno JN; Suarez G; Miller N; Kolber MA; Holder DJ; Shivaprakash M; DeAngelis DM; Wright JL; Schleif WA; Emini EA; Condra JH
AIDS; 2003 Sep; 17(13):1933-9. PubMed ID: 12960826
[TBL] [Abstract][Full Text] [Related]
7. Activity of a ritonavir plus saquinavir-containing regimen in patients with virologic evidence of indinavir or ritonavir failure.
Deeks SG; Grant RM; Beatty GW; Horton C; Detmer J; Eastman S
AIDS; 1998 Jul; 12(10):F97-102. PubMed ID: 9677159
[TBL] [Abstract][Full Text] [Related]
8. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load.
Arnaiz JA; Mallolas J; Podzamczer D; Gerstoft J; Lundgren JD; Cahn P; Fätkenheuer G; D'Arminio-Monforte A; Casiró A; Reiss P; Burger DM; Stek M; Gatell JM;
AIDS; 2003 Apr; 17(6):831-40. PubMed ID: 12660530
[TBL] [Abstract][Full Text] [Related]
9. Low-dose indinavir in combination with low-dose ritonavir: steady-state pharmacokinetics and long-term clinical outcome follow-up.
Justesen US; Levring AM; Thomsen A; Lindberg JA; Pedersen C; Tauris P
HIV Med; 2003 Jul; 4(3):250-4. PubMed ID: 12859324
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors.
Chetchotisakd P; Anunnatsiri S; Mootsikapun P; Kiertiburanakul S; Anekthananon T; Bowonwatanuwong C; Kowadisaiburana B; Supparatpinyo K; Ruxrungtham K;
HIV Med; 2007 Nov; 8(8):529-35. PubMed ID: 17944686
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the efficacy, safety and predictive value of HIV genotyping using distinct ritonavir-boosted protease inhibitors.
Barreiro P; Camino N; de Mendoza C; Valer L; Núñez M; Martín-Carbonero L; González-Lahoz J; Soriano V
Int J Antimicrob Agents; 2002 Dec; 20(6):438-43. PubMed ID: 12458138
[TBL] [Abstract][Full Text] [Related]
12. Impact of drug levels and baseline genotype and phenotype on the virologic response to amprenavir/ritonavir-based salvage regimens.
Valer L; González de Requena D; de Mendoza C; Martin-Carbonero L; González-Lahoz J; Soriano V
AIDS Patient Care STDS; 2004 Jan; 18(1):1-6. PubMed ID: 15006188
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of salvage therapy containing ritonavir and saquinavir after failure of single protease inhibitor-containing regimens.
Hall CS; Raines CP; Barnett SH; Moore RD; Gallant JE
AIDS; 1999 Jul; 13(10):1207-12. PubMed ID: 10416524
[TBL] [Abstract][Full Text] [Related]
14. Comparison of two indinavir/ritonavir regimens in the treatment of HIV-infected individuals.
Acosta EP; Wu H; Hammer SM; Yu S; Kuritzkes DR; Walawander A; Eron JJ; Fichtenbaum CJ; Pettinelli C; Neath D; Ferguson E; Saah AJ; Gerber JG;
J Acquir Immune Defic Syndr; 2004 Nov; 37(3):1358-66. PubMed ID: 15483465
[TBL] [Abstract][Full Text] [Related]
15. Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome.
Deeks SG; Hellmann NS; Grant RM; Parkin NT; Petropoulos CJ; Becker M; Symonds W; Chesney M; Volberding PA
J Infect Dis; 1999 Jun; 179(6):1375-81. PubMed ID: 10228057
[TBL] [Abstract][Full Text] [Related]
16. The cumulative occurrence of resistance mutations in the HIV-1 protease gene is associated with failure of salvage therapy with ritonavir and saquinavir in protease inhibitor-experienced patients.
Karmochkine M; Si Mohamed A; Piketty C; Ginsburg C; Raguin G; Schneider-Fauveau V; Gutmann L; Kazatchkine MD; Belec L
Antiviral Res; 2000 Sep; 47(3):179-88. PubMed ID: 10974370
[TBL] [Abstract][Full Text] [Related]
17. Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Marcelin AG; Affolabi D; Lamotte C; Mohand HA; Delaugerre C; Wirden M; Voujon D; Bossi P; Ktorza N; Bricaire F; Costagliola D; Katlama C; Peytavin G; Calvez V
J Med Virol; 2004 Sep; 74(1):16-20. PubMed ID: 15258963
[TBL] [Abstract][Full Text] [Related]
18. Indinavir plasma concentrations and resistance mutations in patients experiencing early virological failure.
González de Requena D; Gallego O; de Mendoza C; Corral A; Jiménez-Nácher I; Soriano V
AIDS Res Hum Retroviruses; 2003 Jun; 19(6):457-9. PubMed ID: 12882654
[TBL] [Abstract][Full Text] [Related]
19. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy.
Kempf DJ; Isaacson JD; King MS; Brun SC; Sylte J; Richards B; Bernstein B; Rode R; Sun E
Antivir Ther; 2002 Sep; 7(3):165-74. PubMed ID: 12487383
[TBL] [Abstract][Full Text] [Related]
20. Genotypic resistance analyses in nucleoside-pretreated patients failing an indinavir containing regimen: results from a randomized comparative trial: (Novavir ANRS 073).
Descamps D; Joly V; Flandre P; Peytavin G; Meiffrédy V; Delarue S; Lastère S; Aboulker JP; Yeni P; Brun-Vézinet F
J Clin Virol; 2005 Jun; 33(2):99-103. PubMed ID: 15911424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
